CATX — Perspective Therapeutics, Inc.
$1.61-28.76%
Last close: · regular session
Last 60 sessions
CATX closed at $1.61 (-28.76%) on Oct 23, 2026. Float: 95.1M shares. Latest SEC filing: 8-K on Oct 1, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for CATX in the TickerWise workspace.
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
Company profile
- Sector: Healthcare
- Industry: Medical - Devices
- Country: US
- Exchange: AMEX
- Employees: 138
- Website: https://www.perspectivetherapeutics.com
Latest SEC filings for CATX
Latest CATX news
- Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors Read article
- Perspective Therapeutics (NYSEAMERICAN:CATX) Given “Buy” Rating at BTIG Research Read article
- Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium Read article
- Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Stock Now Rated “Buy” by Sell-Side Analysts Read article
- Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026 Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.